[ad_1] After the market close Thursday, Ardelyx Inc (NASDAQ: ARDX) reported Q4 FY22 Ibsrela sales of $8.7 million and $15.6 million for FY22. The…
Read More »
[ad_1] After the market close Thursday, Ardelyx Inc (NASDAQ: ARDX) reported Q4 FY22 Ibsrela sales of $8.7 million and $15.6 million for FY22. The…
Read More »